Tenderwize
Retour à la recherche

Open-house Lenograstim rebate agreement

Techniker Krankenkasse·Hamburg, Germany·Deadline Dec 30, 2027 · 491 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-30 - Lenograstim

46/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

46 / 100

Complexité

58 / 100

Facteurs de risque

Portal submission is not allowed; contracts must be sent by email with qualified electronic signature or by post, which...

Participation is restricted to pharmaceutical undertakings for the relevant product, with seat and authorisation requir...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Dec 2027
  • Conclusion of rebate agreements for the active substance Lenograstim under an open-house procedure.
  • Supply of pharmaceutical products (CPV 33600000).
Afficher le résumé complet

Open-house supply arrangement for Lenograstim pharmaceutical products in Germany, led by Techniker Krankenkasse with HEK and hkk participating. The notice states no exclusivity, no individual negotiations, and uniform terms for all eligible pharmaceutical companies. Contracting can occur throughout the term, but the agreement ends no later than 31.12.2027. Submission is not via the portal; contracts must be sent by email with qualified electronic signature or by post, with portal communication used for questions. No contract value is stated.

Risques

Portal submission is not allowed; contracts must be sent by email with qualified electronic signature or by post, which...

Participation is restricted to pharmaceutical undertakings for the relevant product, with seat and authorisation requir...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Applicant must be a pharmaceutical undertaking within the meaning of Section 4(18) AMG for the offered medicinal products.
  • Applicant must have its seat in the AMG territory, another EU Member State, or another EEA state.
  • Applicant must hold a valid marketing authorisation for the relevant medicinal product(s), or otherwise be entitled to place them on the market in its own name.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open-house Lenograstim rebate agreement

Open-house contract for pharmaceutical rebate agreements under Section 130c(1) SGB V for the active substance Lenograstim. Scope is nationwide in Germany. The lot information comes from structured data and the notice text.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Dec 2025 - Dec 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Dec 30, 2027

Détails de la procédure

Date de publication
23 Apr 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
282722-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3